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Abstract
The clinical signiﬁcance of prolonged viral shedding (PVS) and viral load (VL) dynamics has not been sufﬁciently assessed in hospitalized
patients with pandemic 2009 inﬂuenza A(H1N1). We performed a prospective study of adults with conﬁrmed inﬂuenza A(H1N1) virus
infection admitted to our hospital from 20 September 2009 to 31 December 2009. Consecutive nasopharyngeal swabs were collected
every 2 days during the ﬁrst week after diagnosis, and then every week or until viral detection was negative. Relative VL was measured
on the basis of haemagglutinin and RNaseP gene analysis. PVS was deﬁned as positive detection of inﬂuenza A(H1N1) virus by real-time
RT-PCR at day 7 after diagnosis. We studied 64 patients: 16 (25%) presented PVS. The factors associated with PVS were admission to
the intensive-care unit (69% vs. 33%, p 0.02), purulent expectoration (75% vs. 44%, p 0.04), higher dosage of oseltamivir (62.5% vs. 27%,
p 0.016), corticosteroid treatment (50% vs. 21%, p 0.05), mechanical ventilation (MV) (50% vs. 12.5%, p 0.004), and longer stay (34 vs. 7
median days, p 0.003). Multivariate analysis revealed the factors independently associated with PVS to be immunosuppression (OR 5.15;
95% CI 1.2–22.2; p 0.03) and the need for MV (OR 11.7; 95% CI 2.5–54.4; p 0.002). VL at diagnosis correlated negatively with age and
septic shock. VL dynamics of patients with acute respiratory distress syndrome and/or mortality were very different from those of
other patients. PVS was detected in 25% of hospitalized patients with pandemic 2009 inﬂuenza A(H1N1) and was strongly associated
with immunosuppression and the need for MV. Diagnostic VL and viral clearance varied with the clinical course.
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Introduction
Inﬂuenza is a well-known cause of acute respiratory disease.
It is generally a self-limiting infection with systemic and respi-
ratory symptoms, and usually resolves after 3–6 days in most
patients. Viral clearance in the respiratory tract occurs after
3–5 days [1]. However, a complicated course consisting of
severe respiratory illness, exacerbation of underlying diseases
and the need for intensive care has been reported for
some patients [2,3]. The recently described pandemic
inﬂuenza A(H1N1) virus had a more aggressive course in
speciﬁc populations, such as young patients and pregnant
women [4,5].
Persistence of viral shedding and the dynamics of viral load
(VL) have received little attention in hospitalized patients
with seasonal or pandemic inﬂuenza. Most reports assess the
impact of antiviral therapy [6–8], and data regarding the sig-
niﬁcance of prolonged viral shedding (PVS) and VL as mark-
ers of poor outcome are anecdotal [6,9].
We conducted a prospective study of the frequency of
PVS and the dynamics of VL in order to assess epidemiologi-
cal and prognostic data among hospitalized patients with pan-
demic inﬂuenza A(H1N1).
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Materials and Methods
Study design and setting
We performed a prospective study of adult patients
(>16 years) with laboratory-conﬁrmed inﬂuenza A(H1N1)
virus infection who were admitted consecutively to our hos-
pital from 20 September to 31 December 2009.
Ours is a large, general, tertiary teaching hospital currently
serving a population of approximately 715 000 inhabitants in
Madrid, Spain. The hospital has 1550 beds and includes all
medical and surgical specialties, including solid organ (heart,
liver, and kidney) and bone marrow transplant programmes.
Study patients had laboratory-conﬁrmed inﬂuenza A(H1N1)
virus infection and had been hospitalized for at least 48 h.
Written informed consent was obtained, and consecutive
nasopharyngeal swabs were collected every 2 days during the
ﬁrst week after diagnosis, and then every week or until viral
detection was negative. Clinical data were recorded with the
use of a pre-established protocol that included the following:
demographic characteristics; underlying diseases; inﬂuenza
vaccination status; clinical, laboratory and radiographic ﬁndings
at presentation; data on treatment; inﬂuenza-related complications;
and outcome. The hospital ethics committee approved the study.
During the study period, patients with inﬂuenza-like illness
were diagnosed and treated according to a standard proto-
col. Nasopharyngeal swabs were taken in all suspected cases,
and patients were admitted if they developed serious medical
conditions or presented severe underlying diseases. Droplet
precautions were implemented, and oseltamivir was started
until the results of viral detection were available. Patients
were then treated and discharged according to usual clinical
practice.
Deﬁnitions
We deﬁned PVS as the detection of inﬂuenza A(H1N1) virus
by real-time RT-PCR on day 7 after diagnosis.
On the basis of the underlying diseases and the severity of
illness at presentation, we divided our patients into four risk
groups: (i) patients presenting acute respiratory failure or
septic shock that required admission to the intensive-care
unit; (ii) immunocompromised patients (i.e. patients with
haematological malignancy (with or without bone marrow
transplantation), human immunodeﬁciency virus infection,
inﬂammatory diseases under biological or immunosuppres-
sant treatment, and with solid organ transplant); (iii) patients
with chronic comorbid conditions, such as older age
(>65 years), a body mass index ‡30, chronic obstructive
pulmonary disease, including asthma, cardiovascular disease
excluding isolated hypertension, active cancer, chronic renal
failure, chronic liver disease, diabetes mellitus, haemoglobin
disease, and altered mobilization of respiratory secretions;
and (iv) pregnant women.
Acute respiratory distress syndrome (ARDS) and septic
shock were deﬁned with the use of standard criteria [10,11].
Sample processing and inﬂuenza A(H1N1) virus detection
The nasopharyngeal swabs were preserved in 1 mL of viral
transport medium and stored at 4C for no more than 48 h
until processing. Viral RNA was extracted from 200 lL of
the sample in a Nuclisens EasyMag device (bioMe´rieux, Box-
tel, The Netherlands), following the manufacturer’s instruc-
tions, eluted in 60 lL of elution buffer, and maintained at
4C if it was analysed immediately or at )70C until assay.
Inﬂuenza A(H1N1) virus was detected by real time RT-PCR,
following the WHO/CDC protocol, in a Stratagene MX3000
thermocycler (Stratagene, La Jolla, CA, USA).
Viral quantiﬁcation
VL was determined retrospectively in diagnostic specimens
and in most of the consecutive specimens.
Quantiﬁcation of inﬂuenza A(H1N1) virus was performed
by real-time RT-PCR in a LightCycler 2.0 device, with the
RealTime ready Inﬂuenza A/H1N1 Detection Set and Real-
Time ready RNA virus Master (Roche Diagnostics, Mannheim,
Germany). Two independent reactions were performed to
quantify the viral haemagglutinin and human RNaseP genes by
means of speciﬁc standard curves included in each of the
assays. Relative quantiﬁcation of inﬂuenza A(H1N1) virus was
achieved by normalizing the number of haemagglutinin targets
to the number of RNaseP targets in the specimen. VL was
expressed as relative quantiﬁcation units.
To evaluate the reproducibility of the assay, three aliquots
of a selection of specimens were analysed on three consecu-
tive days, leading to a standard deviation of 0.018 ± 0.018. The
analytical sensitivity of the assay was 2.83 log10 copies/mL.
To analyse VL dynamics over time, we divided patients
into six groups (0, 2–4, 5–7, 8–10, 11–13, and 14–16)
according to the number of days after diagnosis. The avail-
able values for each speciﬁc time-point were averaged.
Statistical analysis
In the univariate analysis, categorical variables were com-
pared by use of the chi-square test. The non-normally dis-
tributed continuous variables were compared by use of the
Mann–Whitney U-test, and expressed as the median and in-
terquartile range (IQR). The normally distributed continuous
variables were compared by use of the t-test, and expressed
as the mean and standard deviation (SD). The Spearman rank
correlation coefﬁcient was used to assess the correlation
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between initial viral concentration and age, duration of symp-
toms, time of oseltamivir initiation after illness onset, days of
viral shedding, and length of hospital stay. Stepwise logistic
regression models were used in the multivariate analysis to
analyse risk factors for PVS. Variables with a p-value <0.1 in
the univariate analysis were included in the multivariate
models. Differences were considered to be signiﬁcant for
p-values <0.05. The analysis was carried out with SPSS 15.0
(SPSS, Chicago, IL, USA).
Results
During the study period, 91 patients with laboratory-con-
ﬁrmed inﬂuenza A(H1N1) virus infection were hospitalized
and followed up until discharge. Of these, 64 patients agreed
to participate in the study.
We detected PVS at day 7 in 16 patients (25%), of whom
six (9.3%) continued to present PVS on day 14 after the ini-
tial positive sample.
Patients with PVS were compared with those who did not
present PVS (Table 1). The univariate analysis showed the
factors associated with PVS to be admission to the intensive-
care unit (69% vs. 33%, p 0.02), purulent expectoration (75%
vs. 44%, p 0.04), higher dosage of oseltamivir (150 mg/12 h)
(62.5% vs. 27%, p 0.016), corticosteroid treatment (50% vs.
21%, p 0.05), mechanical ventilation (MV) (50% vs. 12.5%,
p 0.004), and a longer hospital stay (34 vs. 7 median days,
p 0.003). We were unable to demonstrate a signiﬁcant cor-
relation between PVS and mortality (12.5% vs. 8.3%, p 0.63).
The multivariate analysis showed the factors that were
independently associated with PVS to be immunosuppression
(OR 5.15; 95% CI 1.2–22.2; p 0.03) and the need for MV
(OR 11.7; 95% CI 2.5–54.4; p 0.002).
TABLE 1. Comparison of hospitalized patients with pandemic inﬂuenza A(H1N1) who presented prolonged viral shedding
(PVS) and those who did not
Patients with PVS,
N = 16 (25%)
Patients without PVS,
N = 48 (75%) p OR (95% CI) p
Demographic data
Sex
Male 8 (50) 19 (39.6) 0.56
Female 8 (50) 29 (60.4)
Age (mean ± SD) 47.6 ± 17.5 43.9 ± 13 0.37
Risk groups
ICU 11 (68.8) 16 (33.3) 0.02
Immunocompromised 8 (50) 13 (27.1) 0.12 5.15 (1.2-22.2) 0.03
Chronic comorbidity 9 (56.2) 35 (72.9) 0.23
Pregnant women 2 (12.5) 4 (8.3) 0.63
Charlson comorbidity score (median, IQR) 6, 3–7.75 2, 1–6 0.06
Presenting symptoms
Fever 15 (93.8) 45 (93.8) 1
Cough 14 (87.5) 40 (83.3) 1
Sputum production 12 (75) 21 (43.8) 0.04
Headache 0 8 (16.7) 0.18
Myalgia 6 (37.5) 21 (43.8) 0.77
Diarrhoea 4 (25) 8 (16.7) 0.47
Days of symptoms before diagnosis (median, IQR) 2, 1–4.7 2, 0–4 0.59
Initial radiographic ﬁndings
Any inﬁltrate 5 (31.2) 14 (29.8) 1
One-segmented inﬁltrate 1 (6.2) 7 (14.9) 0.66
Bilateral inﬁltrates 6 (37.5) 13 (27.7) 0.53
Interstitial inﬁltrates 2 (12.5) 1 (2.1) 0.15
Treatment
Days of illness at initiation of treatment (median, IQR) 2.5, 0–5 2, 0–4 0.48
Oseltamivir 75 mg/12 h 7 (43.8) 35 (72.9) 0.06
Oseltamivir 150 mg/12 h 10 (62.5) 13 (27.1) 0.016
Antibiotic treatment 16 (100) 40 (83.3) 0.18
Corticosteroids 8 (50) 10 (20.8) 0.05
Inotropic support 3 (18.8) 2 (4.2) 0.09
Oxygen supplementation 8 (50) 14 (29.2) 0.14
Mechanical ventilation 8 (50) 6 (12.5) 0.004 11.7 (2.5-54.4) 0.002
Complications
COPD exacerbation 4 (25) 3 (6.2) 0.06
Asthma exacerbation 1 (6.2) 7 (14.6) 0.66
Bacterial co-infection 6 (37.5) 16 (33.3) 0.77
ARDS 6 (37.5) 6 (12.5) 0.06
Septic shock 3 (18.8) 2 (4.2) 0.09
Outcome
Death 2 (12.5) 4 (8.3) 0.63
Days of hospital stay (median, IQR) 34, 9–50 7, 4.7–20 0.003
Days of ICU stay (median, IQR) 21, 2–49 4.5, 2–14.5 0.20
ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; ICU, intensive-care unit; IQR, interquartile range; SD, standard deviation.
Bold values indicate factors with p < 0.05.
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Relative VL was determined in 58 of the 64 patients (16
with PVS and 42 without), and ranged from 1.17 · 10)3 to
317 relative quantiﬁcation units (median 0.1, IQR 0.02–2.02).
We found a negative correlation between diagnostic VL and
age (r = )0.287, p 0.03). There was no correlation between
diagnostic VL and duration of symptoms (r = )1.94, p 0.14),
time of oseltamivir initiation after illness onset (r = )0.11,
p 0.4), duration of viral shedding (r = )0.4, p 0.09), or length
of hospital stay (r = )0.23, p 0.09). We found a trend towards
higher diagnostic VL in pregnant women (4.1 vs. 0.1, p 0.07)
and in patients with PVS (0.56 vs. 0.08, p 0.08), although this
was lower in patients with septic shock (0.006 vs. 0.14, p 0.03)
and in-hospital mortality (0.02 vs. 0.12, p 0.06) (Table 2).
VL dynamics during hospitalization in all patients and in
those with poor outcome (ARDS and/or death) are shown
in Fig. 1. Viral clearance was different between these groups.
A progressive decrease in VL was observed in all patients
during the shedding period, whereas in those with poor out-
come, a lower initial VL followed by a peak was observed at
day 2–4 after diagnosis. Viral clearance occurred at day 5–7.
Discussion
We found that 25% of patients who were hospitalized with
pandemic inﬂuenza A(H1N1) presented PVS after diagnosis.
PVS was associated with major morbidity as a predisposing
factor as well as complication of the inﬂuenza. We also
observed that VL dynamics in patients with poor outcome
were different from those of the group as a whole.
Current recommendations for respiratory isolation of
patients hospitalized with inﬂuenza have established 7 days as
a standard ﬁgure [12]. Data on PVS in both seasonal and
pandemic inﬂuenza have shown that 22–57% of hospitalized
patients continue to experience viral shedding 7 days after
onset [6,7]. We are not sure whether data on persistence
TABLE 2. Relationship between
diagnostic relative viral load and
clinical characteristics of hospital-
ized patients with pandemic inﬂu-
enza A(H1N1)
Viral load with this
feature (median, IQR)
Viral load without this
feature (median, IQR) p
Risk groups
ICU admission 0.15 (0.02–4.1) 0.10 (0.007–1.7) 0.55
Immunocompromised 0.15 (0.02–1.8) 0.10 (0.016–2.5) 0.73
Chronic comorbidity 0.14 (0.02–2.4) 0.10 (0.007–1.64) 0.96
Pregnant women 4.1 (0.08–58.1) 0.1 (0.02–1.08) 0.07
Vaccination status
Seasonal inﬂuenza vaccination 0.2 (0.02–1.6) 0.1 (0.01–2.7) 0.99
Pandemic inﬂuenza vaccination 12.1 (4.3–19.8) 0.1 (0.02–1.5) 0.06
Prolonged viral shedding 0.56 (0.03–5.9) 0.08 (0.007–0.85) 0.08
Complications
COPD exacerbation 0.45 (0.16–0.45) 0.10 (0.01–2.3) 0.21
Bacterial co-infection 0.05 (0.005–1.44) 0.14 (0.02–2.7) 0.38
ARDS 0.07 (0.01–1.98) 0.12 (0.02–2.3) 0.71
Septic shock 0.006 (0.0005–0.07) 0.14 (0.02–2.7) 0.03
Outcome
Death 0.02 (0.0008–0.17) 0.12 (0.02–2.9) 0.06
ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; ICU, intensive-care unit;
IQR, interquartile range.
Bold values indicate factors with p < 0.05.
Day of measurement Day 0 Day 2–4 Day 5–7 Day 8–10 Day 11–13 Day 14–16
All patients 
Median viral load, IQR 
(No. of patients)
0.1, 0.02–2.0 
(58) 
0.02, 0.002–0.1 
(15) 
0.02, 0.004–0.02 
(15) 
0.01, 0.002–0.17 
(10) 
0.003 
(1)
0.0003 
(1)
Patients with poor outcome  
Median viral load, IQR 
(No. of patients)
0.04, 0.004–0.25 
(11) 
0.11, 0.06–0.11 
(3)
0.001, 0.0008–0.002 
(3)
0.002, 0.002–0.002 
(2)
0 0.0003 
(1)
Median relative viral load
0.00
0.02
0.04
0.06
0.08
0.10
0.12
GR0 GR2–4 GR5–7 GR8–10 GR11–13 GR14–16
All patients
Patients with poor outcome
FIG. 1. Median relative viral load over the course of the infection for the groups (GR) of patients with specimens analyzed on days 0, 2–4, 5–7,
8–10, 11–13 and 14–16.
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mean that the virus is viable and can be transmitted. The
frequency of positive viral culture in respiratory specimens
collected at day 8 after onset has only been assessed in one
study [13], in which a rate of 19% was observed. The poten-
tial for transmission in patients with PVS requires further
study.
PVS as a marker of a severe underlying condition in patients
with seasonal inﬂuenza has been suggested by Lee et al. [6].
The authors related PVS to older age, chronic comorbidity,
and therapy with systemic corticosteroids. Little is known
about the signiﬁcance of PVS in patients with pandemic inﬂu-
enza. In a series of 22 patients with pandemic inﬂuenza A,
younger age was the only factor associated with a longer per-
iod of viral shedding after onset [14]. In our series, we did not
ﬁnd a correlation between PVS and age or chronic comorbidi-
ty, although immunosuppression increased the risk of PVS
ﬁve-fold (p 0.03). The other risk factor independently associ-
ated with PVS was the need for MV (p 0.002).
Most of our patients presented PVS for more than 7 days
and <14 days. Only one patient with leukaemia presented
PVS for more than 4 weeks. PVS for >4 weeks has been
reported in patients with haematological conditions, particu-
larly those with lymphocytopenia [15].
Given the heterogeneous quality of specimens obtained by
nasopharyngeal swab, the need for relative quantiﬁcation in
inﬂuenza A(H1N1) has recently been reported [16,17]. We
developed a reproducible assay to obtain relative quantiﬁca-
tion data at diagnosis and in consecutive samples.
We found that relative VL in the diagnostic specimen cor-
related negatively with age, septic shock, and in-hospital mor-
tality. We did not ﬁnd a correlation between VL at diagnosis
and the presence of major comorbidity, duration of symp-
toms, or early onset of antiviral treatment, as reported by
Lee et al.[6] in patients with seasonal inﬂuenza. Consistent
with To et al.[9], we showed different viral dynamics in
patients with poor outcome than in the study population as
a whole. Patients with ARDS and/or who died in hospital
had a lower initial VL, with a peak at day 2–4 and viral clear-
ance at day 5–7 after diagnosis. The lower initial VL in this
group suggests that replication of inﬂuenza A(H1N1) virus
could be less efﬁcient in the nasopharyngeal tract than in the
lower respiratory tract in patients with a poorer prognosis.
Our study has several limitations. First, we did not per-
form a daily collection of nasopharyngeal specimens; conse-
quently, we could not estimate the overall median duration
of viral shedding. Second, because of the discomfort associ-
ated with collection of consecutive nasopharyngeal swabs,
the number of patients is small, thus limiting conclusions
about prognostic factors. Third, we analysed VL only in the
samples obtained by nasopharyngeal swabbing; therefore, we
could not compare VL in the upper and lower respiratory
tract.
PVS is a common complication in hospitalized patients
with pandemic inﬂuenza, and is associated with longer hos-
pital stay and poorer outcome. Future recommendations
regarding periods of respiratory isolation in hospitalized
patients with inﬂuenza should consider the frequency and
consequences of this phenomenon. The study of viral clear-
ance can identify patients with a poorer prognosis.
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